{
    "clinical_study": {
        "@rank": "40377", 
        "acronym": "ENOXAMED", 
        "arm_group": [
            {
                "arm_group_label": "LOVENOX", 
                "arm_group_type": "Other", 
                "description": "patients are given a curative dose of Enoxaparin (LOVENOX)"
            }, 
            {
                "arm_group_label": "ENOXAMED", 
                "arm_group_type": "Active Comparator", 
                "description": "patients are given a curative dose of Enoxaparin (ENOXAMED)"
            }
        ], 
        "brief_summary": {
            "textblock": "Because of their anti-Xa and ease of administration activity, the Low molecular weight\n      heparin represent an attractive alternative to the unfractionated heparin. Several clinical\n      trials have demonstrated that Low molecular weight heparin was more effective than\n      Unfractionated heparin without increasing bleeding complications. Enoxaparin has been the\n      most studied. Its use is recommended.\n\n      Demonstrate that Enoxamed\u00ae is comparable to that of Lovenox\u00ae in the anti-Xa activity action."
        }, 
        "brief_title": "Enoxamed Study in the Treatment of Acute Coronary Syndromes", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Single-center randomized controlled trial, single-blind, including patient with an acute\n      coronary syndrome confirmed, to measure the anti-Xa activity between H0 and H4.the study was\n      done on two groups ; ENOXAMED\u00ae group : In this case the patient receives an injection of\n      enoxaparin ( ENOXAMED\u00ae ; Unimed Laboratories) intravenously. Curative dose (100 IU/10 kg).\n\n      Control group ( LOVENOX \u00ae ) In this case the patient receives LOVENOX intravenous injection\n      curative dose of 100 kg IU/10 ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age over 18 year old\n\n          -  With an acute coronary syndrome confirmed\n\n        Exclusion Criteria:\n\n          -  Age less than 18 years\n\n          -  Persistent ST- segment elevation\n\n          -  Contre indication of enoxaparin and heparin in general.\n\n          -  Patient participating in another study,\n\n          -  Pregnant or nursing women\n\n          -  patients taking an anticoagulant in the last three months,\n\n          -  Patients with coagulopathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152423", 
            "org_study_id": "ENOXAMED"
        }, 
        "intervention": [
            {
                "arm_group_label": "LOVENOX", 
                "intervention_name": "LOVENOX", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ENOXAMED", 
                "intervention_name": "ENOXAMED", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Enoxaparin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "enoxaparin", 
            "Enoxamed", 
            "lovenox", 
            "anti Xa", 
            "acute coronary syndrome"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "official website", 
            "url": "http://www.urgencemonastir.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Monastir", 
                    "country": "Tunisia", 
                    "zip": "5050"
                }, 
                "name": "Emergency Department of University Hospital of Monastir"
            }
        }, 
        "location_countries": {
            "country": "Tunisia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of the Anti Xa Activity in the Enoxaparin for Acute Coronary Syndromes Admitted to the Emergency. Randomized Clinical Trial ENOXAMED Versus LOVENOX", 
        "overall_official": {
            "affiliation": "University hospital of Monastir", 
            "last_name": "Nouira Samir, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Tunisia: Ministry of Public Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare the Anticoagulant Activity (measured in a UI per ml in a reference laboratory) of Two Formulations of Enoxaparin [ENOXAMED \u00ae Versus LOVENOX \u00ae], Conducted on Two Parallel Groups of Patients Admitted to Emergency for Acute Coronary Syndrome", 
            "measure": "anti Xa activity (UI/ml)", 
            "safety_issue": "No", 
            "time_frame": "at baseline and after 4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152423"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Monastir", 
            "investigator_full_name": "Nouira", 
            "investigator_title": "Head of departement", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Evaluate the Clinical and Biological Tolerance of the Study Treatments.", 
            "measure": "adverse events", 
            "safety_issue": "No", 
            "time_frame": "during hospital stay with an average of 5 days"
        }, 
        "source": "University of Monastir", 
        "sponsors": {
            "collaborator": {
                "agency": "University Hospital Fattouma Bourguiba", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Monastir", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}